Sector: Health Care
Director information for MADRIGAL PHARMACEUTICALS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Bill Sibold | President and Chief Executive Officer and Class II Director | 59 | ["More than 30 years of experience in the biopharmaceutical industry","Executive Vice President, Specialty Care of Sanofi","President, Sanofi North America","Senior Vice President, Global Franchise Head, Multiple Sclerosis, Oncology & Immunology, Sanofi Genzyme","Chief Commercial Officer of Avanir Pharmaceuticals, Inc.","President and CEO of Lycera Corp","Senior Vice President, U.S. Commercial for Biogen Inc.","Holds a B.A. in Molecular Biophysics and Biochemistry from Yale University","Holds an M.B.A. from Harvard Business School"] | [] | 2026 |
| Daniel J. Brennan | Class I Director | 60 | ["Previously served as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation","Responsible for several company functions including global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations and corporate business development","Joined Boston Scientific in 1996 and held roles of increasing responsibility within finance","Previously served on the board of directors of Nuance Corporation from September 2018 until March 2022","Holds a B.S. in Finance and Investments and an M.B.A. from Babson College","Certified public accountant","Expertise in business development strategies, capital management and financial reporting"] | ["Compensation"] | 2026 |
| Jacqualyn A. Fouse, Ph.D. | Class III Director | 64 | ["Previously served as Chief Executive Officer of Agios Pharmaceuticals, Inc.","Served as Executive Chair of Dermavant Sciences, Inc.","Served in various leadership capacities at Celgene Corporation","Chief Financial Officer of Bunge Limited","Senior Vice President, Chief Financial Officer and Corporate Strategy at Alcon Laboratories, Inc.","Held a variety of senior leadership roles with international companies in Europe"] | ["Science and Technology","Nominating and Governance","Compensation"] | 2026 |
| James M. Daly | Class I Director | 64 | ["Over 30 years of experience in the biopharmaceutical industry","Executive Vice President and Chief Commercial Officer at Incyte from 2012 until 2015","Various leadership positions at Amgen, Inc. from 2002 to 2011","Over 16 years with Glaxo Wellcome/GlaxoSmithKline","Served on the board of directors of Bellicum Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc.","B.S. in Pharmacy and an M.B.A. from the University at Buffalo"] | ["Science and Technology","Nominating and Governance"] | 2026 |
| Julian C. Baker | Independent Chairman of the Board of Directors and Class I Director | 59 | ["Managing Member of Baker Bros. Advisors LP","Experience investing in life sciences companies","Experience serving on board of directors of other public companies in the life sciences industry"] | ["Audit","Compensation"] | 2026 |
| Paul A. Friedman, M.D. | Director | ["extensive experience in clinical development","evaluating research and development programs"] | ["Science and Technology Committee"] | 2026 | |
| Paul A. Friedman, M.D.(1) | Director | 83 | [] | [] | 2026 |
| Raymond Cheong, M.D., Ph.D. | Chairman; Class III Director | 44 | ["Managing Director at BBA","Experience investing in many life sciences companies","Experience serving on the boards of directors of other public companies in the life sciences industry"] | ["Science and Technology Committee","Science and Technology","Nominating and Governance","Compensation"] | 2026 |
| Rebecca Taub, M.D. | Senior Scientific and Medical Advisor and Former President of Research & Development and Chief Medical Officer and Class II Director | 74 | ["Chief Medical Officer of Madrigal from July 2016 to April 2025","President, Research & Development from June 2019 to April 2025","Senior Vice President, Research and Development of VIA Pharmaceuticals, Inc. from 2008 to 2011","Vice President, Research, Metabolic Diseases at F. Hoffmann-La Roche AG from 2004 to 2008","Various capacities at Bristol-Myers Squibb Company and DuPont from 2000 through 2003","Tenured Professor of Genetics and Medicine at the University of Pennsylvania from 1987 to 2002","Adjunct professor","Assistant Professor at the Joslin Diabetes Center of Harvard Medical School","Author of more than 120 research articles"] | [] | 2026 |
| Richard S. Levy, M.D. | Class III Director | 68 | ["Executive Vice President and Chief Drug Development Officer at Incyte from January 2009 until April 2016","Senior Vice President of Drug Development at Incyte from August 2003 to January 2009","Vice President, Biologic Therapies, at Celgene from 2002 to 2003","Various executive positions with DuPont Pharmaceuticals Company from 1997 to 2001","Increasing responsibility in clinical research and regulatory affairs at Novartis AG from 1991 to 1997","Part-time Senior Advisor for BBA from December 2016 to May 2019","Board Certified in Internal Medicine and Gastroenterology"] | ["Audit","Science and Technology","Nominating and Governance","Science and Technology Committee"] | 2026 |
